Homeopathy Papers

Clinical Study of Sars Cov-2019 Nosode -Part III Clinical Trial of Sarscov-2019 Nosode (06 Ck) on Healthy Individuals

Clinical Study of Sars Cov-2019 Nosode -Part III  Clinical Trial of Sarscov-2019 Nosode (06 Ck) on Healthy Individuals 1

Homeopath Chetna Shukla reports on her proving of Sars Cov-2 19 Nosode on 12 healthy subjects. The subjects were tested before and after taking the nosode and their subjective symptoms were recorded, as well as some laboratory tests.

This is part three of a series of three articles. Part 3 is about evidence-based homoeopathy. It is to study and illustrate the effect of SarsCov-2 19 Nosode in 06 CK in a Before-After study with relation to inflammatory markers associated with Covid-19 infection in a small group of healthy individuals.

Part I was published in the September 2020 issue of this journal. Part 1 is about evidence-based homoeopathy, depicting associated inflammatory markers of 10 cases that are corrected by SarsCov-2 19 Nosode (SCN) in treatment of acute Covid-19 infection. Part I is about proving efficacy of SCN in 30 CK, a high potency, in disease. The 30 CK according to Avogadro’s number cannot have in it even traces of the starting material.

Part 2 is published also in this October 2020 issue. Part 2 is about evidence-based homoeopathy, depicting laboratory findings that are corrected by SarsCov-2 19 Nosode 30 Ck in treatment of Post Covid-19 sequelae (ILF- 2 cases).

Keywords: SarsCov-2 19 Nosode 06CK, clinical proving, before-after, healthy humans, inflammatory markers, Covid-19, safe, effective

Summary: I have conducted 28 provings in 28 years of my homoeopathic practice in different potencies such as 12 Ck, 30 Ck, 200 Ck, 50 millesimal potencies.  I was considering conducting a proving of the new medicine Sarscov-2 19 Nosode (SCN) that I prepared in June 2020.

I came across the proving notes on Covid-19 Nosode of Marilyn Freedman and Hannah Shalom (Toronto, Canada) conducted in March 2020 in 1M and 10 M potency.  Therefore, I decided to prove this medicine differently so that it aligns with the evidence-based medicine era trend. The method used was to prove the Nosode in low potency, 06 CK and record its effects in a before-after study with relation to inflammatory markers in healthy individuals.

I didn’t want my study to be hindered by the dictates of Avogadro’s number and so I chose the 06 Ck potency. The dictate of Avogadro’s number is that chemically all potencies above 12 C will be just the vehicle and contain none of the original material.

Hahnemann’s Organon, 6th Edition, Boericke’s translation aphorism §108 on drug proving says…

Aphorism § 108

There is, therefore, no other possible way in which the peculiar effects of medicines on the health of individuals can be accurately ascertained – there is no sure, no more natural way of accomplishing this object, than to administer the several medicines experimentally, in moderate doses, to healthy persons, in order to ascertain what changes, symptoms and signs of their influence each individually produces on the health of the body and of the mind; that is to say, what disease elements they are able and tend to produce1, since, as has been demonstrated (§§ 24-27), all the curative power of medicines lies in this power they possess of changing the state of man’s health, and is revealed by observation of the latter”.

Part III: Drug Proving: This is essentially a proving of SCN in 06 CK. This study was aimed at ascertaining the effects of the SarsCov-2 19 Nosode in 06 CK on inflammatory markers associated with Covid-19 in healthy humans.

In any proving, we need to ascertain ‘symptoms and signs’ (§ 108); A symptom is subjective, that is, apparent only to the patient. A common example is burning pain or nausea. A sign is any objective evidence of a disease that can be observed by others. A common example is a skin eruption or redness secondary to inflammation of the eye.

In my interpretation, a sign can also mean changes in blood chemistry, haematology, pathology and histology. With the proving of SCN 06 Ck, I was aiming to ascertain symptoms and signs of its influence on the health of the individuals. My emphasis is on the ‘signs’. The subjective symptoms that volunteer code RSP, JG and KDW exhibited are mentioned collectively in the article after the study on inflammatory markers.

Why 06 CK potency?

Mother tinctures and all dilutions contain alcohol, as do the orally administered drops prepared in an alcohol solution. Alcohol is effective against influenza virus. Ethyl alcohol (70%) is a powerful broad-spectrum germicide and is considered generally superior to isopropyl alcohol.

The Sarscov-2 19 Nosode is prepared in 90%v/w of ethyl alcohol. 06Ck is diluted to 10 raise to -12 (10-12) while being succussed at each step. In this circumstance the virus has no scope to be active and potent to affect the individual adversely.

Let us understand the scale of our homoeopathic dilutions…

Centesimal Scale  1:100   Ratio of dilution Special Note
1C 1: 100 Low potency
3C 10 raised to -6 (10-6)
4C 10 raised to -8 (10-8) Allowable concentration of Arsenic in US drinking water that is 0.05 mg/L
6C 10 raised to -12

(10-12)

Applying the equation of 12C we have in 6C a more than 100% possibility of containing more than one molecule of original material if one mole of the original substance was used
The Avogadro constant (NA or L) is the proportionality factor that relates the number of constituent particles (usually moleculesatoms  or ions) in a sample with the amount of substance in that sample. Its SI unit is the reciprocal mole, and it is defined as NA = 6.02214076×1023 mol−1
12C 10 raised to -24 (10-24 ) Has a 60% probability of containing one molecule of original material if one mole of the original substance was used.
One mole of a substance is equal to 6.022×1023   units of that substance (such as atoms, molecules or ions)
30C 10 raised to – 60

(10-60)

Dilution advocated by Dr Hahnemann

In the 06 CK of the SCN, we definitely have a more than 100% possibility of containing more than one molecule of original material if one mole of the original substance was used. In homoeopathic proving the molecule of original material is being introduced in an open system, the gastrointestinal tract. The study is to ascertain what effect the molecule of original material will have on the immune system of the individual ingesting it (refer to table above).

Schema of Study

The clinical study (drug proving) of SCN in 06 Ck pertains to evaluating its effect in 12 healthy human beings before and after receiving the medicine orally. The healthy individuals who volunteered were tested before and after for inflammatory markers.

  1. Before: Inflammatory markers (CBC, ESR, CRP, SGOT, SGPT, Ferritin and igG for Covid or AntiSarscov-2 Antibodies ) before the ingestion of medicine. The tests were conducted to verify that they did not have the predisposition to be potential candidates for Covid-19 infection.
  2. After 8-10 days: CBC, ESR, CRP and Anti Sarscov-2 Antibodies to be repeated between 8-12 days of receiving of SCN 06CK.
  1. After 14-18 days: AntiSarscov-2 Antibodies to be repeated between 14-18 days after receiving of SCN 06CK. Testing 8-10 days and 14-18 days after is based on the available information that IgG antibodies are produced from day 5 to 7 of the infection and levels peak around 10 to 14 days post infection and last for several months. A new study from Iceland provides reassurance that our antibodies to the coronavirus that causes covid-19 can last at least four months.

Clinical Study of Sars Cov-2019 Nosode -Part III  Clinical Trial of Sarscov-2019 Nosode (06 Ck) on Healthy Individuals 2

 Figure:  Estimated variation over time in diagnostic tests for detection of SARS-CoV-2 Infection relative to symptom onset Source: https://jamanetwork.com/journals/jama/fullarticle/2765837

THE SURPRISE

In all, 12 members volunteered for this study. The ‘Before’ bloodwork of 6 of them established them as reactive for Anti SarsCov-2 antibody and the other 6 were Non-reactive for Anti SarsCov-2 antibody. The 6 reactive volunteers were not known to have suffered from the Covid-19 disease. I was surprised, and I also considered disqualifying the 6 Reactive to AntiSarsCov-2 antibody. On second thought, I decided to flow with what was unfolding. I included all 12 (6 Reactive +6 Non-reactive for Antibody) in the 06CK SCN study.

INSTRUCTIONS FOR THE HEALTHY SUBJECTS GROUP:

  1. One pill daily of 06 CK SCN for 5 days at bedtime (from 26 August to 30 August 2020).
  2. To continue their regular medication in volunteers who have pre-existing illness (diabetes, hypertension etc.). Volunteer Code DBK is on blood thinners/ anti platelets as he had an angioplasty a year ago. He was asked to stop his homoeopathy medicines.
  3. To continue with their daily routine, continue with their regular diet and regimen
  4. The study group was not isolated during and were following their occupation as usual and following the lockdown rules laid by the state government.
  5. Only subject ARS was residing in Surat, Gujarat. All the others were residents of Mumbai, Maharashtra.
  6. All other homoeopathy medicines were discontinued by volunteers during this drug proving. Volunteer Code KGN suffering from tinnitus and stopped all homoeopathy.

Comparison of the inflammatory markers’ values before and after taking the medicine in 06 CK.

Table 1: After 5 days of SCN 06Ck in Non-reactive group  
PEI=Pre Existing Illness: R=Reactive: NR=Non reactive B=Before A=After
  RSP KDS ADS GSJ DBK KGN
Sex F M M F M F
Age 49 32 28 44 73 59
Profession Lawyer Lawyer Lawyer Housewife Doctor Doctor
PEI DM Fatty Liver & Dyspepsia   Adenomyosis on OC pills DM+

HT+IHD

Tinnitus
Hb-B 10.4 14.9 14.3 13.3 13.7 12.38
Hb-A 10.8 15.4 14.5 14.1 13.6 13.2
WBC-B 9000 10500 8100 9500 7200 8280
WBC-A 9200 9700 6900 8800 5500 8300
Neutro-B 72 62 55 61 68 44
Neutro-A 71 63 55 62 67 61
Lympho-B 19 37 44 38 30 49
Lympho-A 19 36 44 36 32 37
ESR-B 7 10 18 35 25 45
ESR-A 11 20 35 40 36 50
CRP-B 2.4 1.1 1.5 3.03 0.5 3.9
CRP-A 2.9 1.4 1.8 2.0 0.5 4.0
SGOT-B only 20 40.1 27 18 38.4 28
SGPT- B only 13 93 44 10.7 25.1 30.1
Ferritin – B only 80.2 189 68 15.03 247 132.46
 AntiSarscov-2 antibodies -B NR

(0.0771)

NR

0.072

NR

0.103

NR

0.083

NR

0.209

NR

0.082

 AntiSarscov-2 antibodies -After- 8th to 10th  Day NR

(0.0785)

NR

0.085

NR

0.112

NR

0.087

NR

0.176

NR

(0.066)

 AntiSarscov-2 antibodies -After- 14th    -18th Day NR

(0.0687)

NR

(0.0)        

NR

(0.04)

NR

(0.072)

NR

(0.070)

NR

(0.065)

 STUDY ON REACTIVE GROUP

Table 2: After 5 days of SCN 06Ck in Reactive group  
PEI=Pre Existing Illness: R=Reactive: NR=Non reactive B=Before A=After
  CNS JG SJG DRD ARS KDW
Sex F M M M M F
Age 53 51 25 41 47 53
Doctor  Shop owner Student Doctor Doctor Artist
PEI   HT Asthma
Hb -B 12.65 15.1 16.1 13.5 15.2 10.9
Hb-A 13.9 15.2 16.0 13.0 15.2 11.0
WBC-B 9550 5900 8100 5300 6410 6400
WBC-A 9900 6300 7700 5200 5450 6100
Neutro-B 50 63 53 57 60 63
Neutro-A 67 67 56 55 54 59
Lympho-B 44 36 46 32 33 36
Lympho-A 32 32 42 33 36 40
ESR-B 35 15 10 6 10 50
ESR-A 33 12 05 9 10 55
CRP-B 1.1 0.5 0.5 3.9 01 1.4
CRP-A 0.6 0.5 0.5 4.47 01 1.6
SGOT-B 38.1 29 30.1 40 12 22.1
SGPT-B 41 31 43.1 49 12 26.1
Ferritin -B 35.82 47.27 84.81 86.2 137 79.26
 AntiSarscov-2 antibodies -B: React

63.90

React

18.74

React

118.8

 

React

4.70

React

1.04

React

57.41

 AntiSarscov-2 antibodies -A:  8thto 10th Day React

57.70

React

18.90

React

118.6

React

64.6

React

1.83

React

51.01

Code DRD showed a significant rise in reactive value. All other volunteers showed an insignificant change in reactive values    
 AntiSarscov-2 antibodies -A : 14 th to 18th Day Since most subjects showed an insignificant change in reactive values the test was not repeated.

SUBJECTIVE SYMPTOMS OBSERVED AFTER 5 DAYS OF SCN 06 CK:

Volunteers with code RSP, JG and KDW mentioned some symptoms that are listed below. Others did not exhibit any symptoms at all.

  1. Feverish feeling but no recorded temperature. Hot feeling in the body.
  2. Eyes heavy.
  3. Body ache; Body feels heavy, feet feel heavy while walking, no desire to walk. Energy levels very low. Tired feeling all the time.
  4. Body and mind felt sluggish, no desire to work
  5. Sleep fitful, wakes up often due to aches and pains.
  6. Rumblings in abdomen. Bowels regular but feels clear.

CONCLUSION: EFFECT OF SCN 06 CK ON HEALTHY HUMANS   

  1. Part I and II of this article demonstrated the curative powers of SCN 30 CK in disease. The SCN is effective as a medicine in Covid-19 infection.
  2. The above study in healthy human beings (Part III) demonstrated the following…

Observation 1: The SCN 06 CK did not alter the inflammatory markers in the 12-member study group- both Reactive and Non-reactive group.  

Deduction 1: That SCN 06 Ck has no adverse effect even at such low potency. The SCN even at low potency 06CK is safe.

Observation 2: The SCN 06CK did not adversely alter the reactivity in the 06 member study group that was Reactive to AntiSarsCov -2 Antibodies   before starting the study.

Deduction 2: Only in 1 subject (code DRD) was there a significant rise in the antibody titer from 4.70 to 64.6. The SCN 06CK also did not adversely alter the titer value of Antibodies (by causing reduction) in the 6-member study group that was Reactive to AntiSarsCov -2 Antibodies. The SCN even at such low potency as 06Ck is safe and has no adverse effects on the antibody titer.

Observation 3: The SCN 06CK did not alter the Non-reactivity in the  06-member study group  that was Non-reactive to AntiSarsCov -2 Antibodies  before starting the study.

Deduction 3: That SCN 06Ck has no adverse effect even at such low potency. The SCN even at low potency 06CK is safe.

CONCLUSION:  SCN 06 CK is safe and has no adverse effect in healthy individuals.

FINAL CONCLUSION: Part I of this series regarding Study I proved the efficacy of the SarsCov-2 19 Nosode 30 CK in correcting the inflammatory markers associated in the Covid-19 disease. The 30 CK potency of SCN defied Avogadro’s number and still proved to be effective. It passed the test of its capability of assisting the vital force in curing the disease.

                                        Part II of the article with cases proved the efficacy of the Sarscov2-19 Nosode in treating sequelae to Covid-19 infection- Lung damage-ILF. The 30 CK potency of SCN passed the test of its capability of assisting the vital force in curing the disease.

Part III of this  series regarding drug proving in healthy human beings, proved the safety of Sarscov-2 19 Nosode in low potency, as low as 06CK.

THIS STUDY PROVES: SARSCOV-2 19 NOSODE IS SAFE AND EFFECTIVE.

Note: This is the first phase of study with a sample group of 12 individuals. These findings along with all laboratory investigations will be submitted to the appropriate regulatory bodies / authorities in homoeopathy. This drug trial has been self-funded. The plan is to conduct the study with more than 50 healthy individuals. The finances for laboratory investigations for study in a larger group call for support from CCRH/ AYUSH ministry / government institutions.  I am continuing treating Covid-19 active cases and its sequelae in my clinic with SCN and will submit another article on the same in the near future with many more cases.

For more information, contact Dr. Chetna Shukla:

[email protected] 

References:

  1. https://medcraveonline.com/IJCAM/avogadro-limit-washed-out-by-nano-associates-of-water-which-continue-as-information-carriers-in-serial-dilutions-and-end-up-with-generalized-concept-of-medicines.html
  2. https://mumbaimirror.indiatimes.com/ coronavirus/ news/cured-of-covid-22-return-to-kem-with-pulmonary-fibrosis/articleshowprint/ 77340422 .cms? prtpage=1: Mumbai Mirror 4 August 2020:
  3. https://www.thehindubusinessline.com/news/world/90-of-recovered-covid-19-patients-in-wuhan-still-have-damaged-lungs-study/article32302989.ece#: Hindu Business
  4. Tocilizumab:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243567/
  5. Tocilizumab: https://en.wikipedia.org/wiki/Tocilizumab
  6. https://www.who.int/news-room/ commentaries/detail/immunity-passports-in-the-context-of-covid-19?gclid=EAIaIQobChMIu9Pzjd-d6wIVCCQrCh2K0gHQEAAYASAAEgKwnPD_BwE:Immunity passports in the context of COVID-19
  7. https://www.futurity.org/war-zones-stress-babies-1099502/: Darlene Kertes
  8. https://www.who.int/water_sanitation_health/dwq/arsenicun5.pdf
  9. https://www.britannica.com/science/Avogadros-number
  10. Use of disinfectants: alcohol and bleach: https://www.ncbi. nlm.nih. gov/ books/ NBK214356/
  11. https://www.cdc.gov/coronavirus/2019ncov/lab/resources/antibody-testshtml#:~:text=Recommendations% 20for% 20persons%20who%20test,SARS%2DCoV%2D2%20infection.
  12. Interpreting Diagnostic Tests for SARS-CoV-2: Figure on : Estimated Variation Over Time in Diagnostic Tests for Detection of SARS-CoV-2 Infection Relative to Symptom Onset : https://pubmed.ncbi.nlm.nih.gov/32374370/
  13. COVID-19 Antibodies Last for at Least Four Months After Recovery: https://www.the-scientist.com/news-opinion/covid-19-antibodies-last-for-at-least-four-months-after-recovery-67907
  14. Infection: https://www.medicinenet.com/script/main/art.asp? articlekey=12923

About the author

Dr Chetna N shukla

Dr Chetna N shukla

Dr Chetna N Shukla is a homeopath and author from Mumbai, India. She has written books on food and provings. Some of her works on provings have been translated into German, Czech and Portuguese. She has been conducting provings since 1996. She has conducted provings of new remedies of Peter Chappell and Harry van der Zee – the PC Cancer, PC Aids and PC Malaria and also the Indian Crow egg, Peacock egg, Indian Duck egg, Python, Indian Mongoose blood, Hippocampus kuda (Sea horse), Turtle shell, Red cap veiled tail gold fish, Armadillo hide (Tatu). In plants Cedrus odorata, Rudraksh, Mangifera indica; in flowers Rosa damask, Hibiscus rosasinensis, Crataegus, spiritual drink Ayahuasca as also Tailed jay butterfly, Donkey’s milk, Snowflakes and Shitake mushroom. She has been collating Global provings (Himalayan Salt, Natural Silver and Terra Indiana) – articles of which have been published in the Links. Apart from provings she has been practicing and working on the book on her concept of ‘Curability Quotient’ in homeopathy.

3 Comments

  • DEAR DRS,
    YOU ARE FULLY AWARE THAT HOMEOPATHY IN INDIA IS FULLY REGULATED BY GOI. IN ORDER TO GET YOUR INVENTION OF SCN APPROVED , YOU ARE REQUESTED TO TAKE ALL YOUR PAPERS, PROVING ON HEALTHY OR SUFFERERS DIRECT TO HEAD OF CCH WHO IS WELL EQUIPPED WITH THE KNOWLEDGE OF ORGANON. HE WILL NEVER SAY THAT MOLECULES ARE NOT TRACEABLE IN THE NOSODE YOU HAVE PREPARED YOU KNOW IN ALL PATHIES THE INGREDIENTS OF MEDICINE ARE TRACEABLE. HOMEOPATHY IS ONLY THE EXCEPTION. SO IT IS OF NO USE TO SUBMIT AND PROVE THE RESULT OF YOUR ACHIEVEMENT TO OTHER PATHIES. PL DO NOT DELAY ITS APPROVAL BY CCH. THE GOI IS GOING TO USE INDIAN VACCINATION OF COV19 FROM 1/11/2020
    REGARDS
    DR C S GUPTA

  • Fascinating and well-designed set of experiments and tests. Thanks so much for your work in this field. I’ll try to get your information out to a few homeopaths in the US.

Leave a Comment